Do the current MS clinical course descriptors need to change and if so how? A survey of the MS community.

Autor: Thompson AJ; Queen Square Multiple Sclerosis Centre, Department of Neuroinflammation, UCL Queen Square Institute of Neurology, NIHR University College London Hospitals Biomedical Research Centre, Faculty of Brain Sciences, University College London, London, UK., Moccia M; Department of Molecular Biology and Molecular Biotechnology, Federico II University of Naples, Naples, Italy Multiple Sclerosis Unit, Policlinico Federico II University Hospital, Naples, Italy., Amato MP; Department NEUROFARBA, Section of Neurosciences, University of Florence, Florence, Italy IRCCS Fondazione Don Carlo Gnocchi, Florence, Italy., Calabresi PA; Department of Neurology and The Solomon H. Snyder Department of Neuroscience, Johns Hopkins University School of Medicine, Baltimore, MD, USA., Finlayson M; School of Rehabilitation Therapy, Queens University, Kingston, ON, Canada., Hawton A; University of Exeter Medical School, University of Exeter, Exeter, UK., Lublin FD; Department of Neurology, Icahn School of Medicine at Mount Sinai, New York, NY, USA., Marrie RA; Departments of Medicine & Community Health Sciences, Max Rady College of Medicine, Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, MB, Canada., Montalban X; Multiple Sclerosis Centre of Catalonia and Department of Neurology-Neuroimmunology, Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Barcelona, Spain., Panzara M; Neurvati Neurosciences, New York, NY, USA., Sormani MP; Department of Health Sciences, University of Genoa, Genoa, Italy IRCCS Ospedale Policlinico San Martino, Genoa, Italy., Strum J; RealTalk MS, Long Beach, CA, USA., Vickrey BG; Department of Neurology, Icahn School of Medicine at Mount Sinai, New York, NY, USA., Coetzee T; National Multiple Sclerosis Society, 733 Third Avenue, New York, NY 10017, USA.; National Multiple Sclerosis Society, New York, NY, USA.

Publikováno v: Multiple sclerosis (Houndmills, Basingstoke, England) [Mult Scler] 2023 Oct; Vol. 29 (11-12), pp. 1363-1372. Date of Electronic Publication: 2023 Sep 11.

FP.12 Application for primary endpoint qualification of the 95th centile of stride velocity (SV95C) in Duchenne muscular dystrophy

Autor: Annoussamy, M., Eggenspieler, D., Seferian, A., Mercuri, E., Straub, V., Muntoni, F., Scoto, M., Poleur, M., Daron, A., Butoianu, N., Mirea, A., Goemans, N., Previtali, S., Tulinius, M., Nascimento, A., Heydemann, P., Panzara, M., Singh, T., Strijbos, P., Servais, L.

Publikováno v: In Neuromuscular Disorders October 2022 32 Supplement 1:S65-S65

The MSOAC approach to developing performance outcomes to measure and monitor multiple sclerosis disability

Autor: LaRocca, NG, Hudson, LD, Rudick, R, Amtmann, D, Balcer, L, Benedict, R, Bermel, R, Chang, I, Chiaravalloti, ND, Chin, P, Cohen, JA, Cutter, GR, Davis, MD, DeLuca, J, Feys, P, Francis, G, Goldman, MD, Hartley, E, Kapoor, R, Lublin, F, Lundstrom, G, Matthews, PM, Mayo, N, Meibach, R, Miller, DM, Motl, RW, Mowry, EM, Naismith, R, Neville, J, Panagoulias, J, Panzara, M, Phillips, G, Robbins, A, Sidovar, MF, Smith, KE, Sperling, B, Uitdehaag, BM, Weaver, J, Multiple Sclerosis Outcome Assessments Consortium (MSOAC)

Publikováno v: Multiple Sclerosis Journal, 24(11), 1469-1484. SAGE Publications Ltd
Multiple Sclerosis (Houndmills, Basingstoke, England)
Multiple Sclerosis Outcome Assessments Consortium (MSOAC) 2018, ' The MSOAC approach to developing performance outcomes to measure and monitor multiple sclerosis disability ', Multiple Sclerosis Journal, vol. 24, no. 11, pp. 1469-1484 . https://doi.org/10.1177/1352458517723718

Background: The Multiple Sclerosis Outcome Assessments Consortium (MSOAC) was formed by the National MS Society to develop improved measures of multiple sclerosis (MS)-related disability. Objectives: (1) To assess the current literature and available

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2c0a745dfe2c0510c571629e202d3b03
https://research.vumc.nl/en/publications/fb260b55-8245-4745-81e8-76c5dc4e2019

Towards Treating Multiple Sclerosis Progression.

Autor: Häusler, Darius^1,2 (AUTHOR) darius.haeusler@med.uni-goettingen.de, Weber, Martin S.^1,2,3 (AUTHOR) martin.weber@med.uni-goettingen.de

Publikováno v: Pharmaceuticals (14248247). Nov2024, Vol. 17 Issue 11, p1474. 15p.

O.28Safety and tolerability of suvodirsen (WVE-210201) in patients with Duchenne muscular dystrophy: results from a phase 1 clinical trial

Autor: Wagner, K., Phan, H., Servais, L., Gidaro, T., Cripe, L., Eagle, M., Muntoni, F., Straub, V., Lonkar, P., Schmitz, S., Lake, S., Hu, X., Panzara, M.

Publikováno v: In Neuromuscular Disorders October 2019 29 Supplement 1:S124-S124